Call for NICE to reverse decision to reject novel osteoporosis drug

The Royal Osteoporosis Society has called on the National Institute for Health and Care Excellence to work with clinicians to ensure patients have equal access to the "life-changing" osteoporosis drug romosozumab.
It is estimated that around 1 in 100 may be at risk of severe osteoporosis

Clinicians are calling for the National Institute for Health and Care Excellence (NICE) to reconsider its provisional decision not to recommend use of the first new osteoporosis medication it has considered for more than a decade.

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Last updated